Paying users zone. Data is covered by 
.
Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Regeneron Pharmaceuticals Inc. (REGN)
Common-Size Balance Sheet: Assets
Difficulty: Beginner
Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: assets
Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).
| Balance sheet item | Description | The company |
|---|---|---|
| Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Regeneron Pharmaceuticals Inc.’s current assets as a percentage of total assets increased from 2016 to 2017 and from 2017 to 2018. |
| Property, plant, and equipment, net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. | Regeneron Pharmaceuticals Inc.’s property, plant, and equipment, net as a percentage of total assets declined from 2016 to 2017 and from 2017 to 2018. |
| Noncurrent assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Regeneron Pharmaceuticals Inc.’s noncurrent assets as a percentage of total assets declined from 2016 to 2017 and from 2017 to 2018. |